Abstract
The development of simultaneous decompensation in cardiac and renal function is a common phenomenon in patients with congestive heart failure. Termed the cardiorenal syndrome (CRS), this joint deterioration in cardiac output and renal filtration is the result of a complex interplay of hemodynamic and neurohormonal factors. Recently, endothelial dysfunction, inflammation and uremia have been recognized as contributors to the crosstalk responsible for the development of CRS. Management strategies for the treatment of CRS involve correction of hemodynamic derangements and regulation of neurohormonal pathways. Future therapies may target more newly recognized components of CRS pathophysiologic development.
Keywords: Cardiorenal syndrome, heart failure, kidney injury, renal failure, venous congestion, volume overload.
Cardiovascular & Hematological Disorders-Drug Targets
Title:The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Volume: 14 Issue: 3
Author(s): Lisa Cohen
Affiliation:
Keywords: Cardiorenal syndrome, heart failure, kidney injury, renal failure, venous congestion, volume overload.
Abstract: The development of simultaneous decompensation in cardiac and renal function is a common phenomenon in patients with congestive heart failure. Termed the cardiorenal syndrome (CRS), this joint deterioration in cardiac output and renal filtration is the result of a complex interplay of hemodynamic and neurohormonal factors. Recently, endothelial dysfunction, inflammation and uremia have been recognized as contributors to the crosstalk responsible for the development of CRS. Management strategies for the treatment of CRS involve correction of hemodynamic derangements and regulation of neurohormonal pathways. Future therapies may target more newly recognized components of CRS pathophysiologic development.
Export Options
About this article
Cite this article as:
Cohen Lisa, The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X14666140701100913
DOI https://dx.doi.org/10.2174/1871529X14666140701100913 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Resident Cardiac Stem Cells
Current Pharmaceutical Design Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Current Gene Therapy Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Patent Selections:
Recent Patents on Regenerative Medicine A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients
Current Drug Safety Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry ACE Inhibitor Delapril Prevents Ca<sup>2+</sup>-Dependent Blunting of I<sub>K1</sub> and Ventricular Arrhythmia in Ischemic Heart Disease
Current Molecular Medicine Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Looking for Organ Damages Due to Anabolic-androgenic Steroids (AAS): Is Oxidative Stress the Culprit?
Mini-Reviews in Organic Chemistry Angiotensin II Roles in Human Vascular Tone Control
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Specificity of Three Vasopressin Receptor Antagonists
Letters in Drug Design & Discovery Using Extracellular Matrix-Derived Peptides to Alter the Microenvironment for Myocardial Repair
Current Vascular Pharmacology